Outcomes), the efficacy and safety of ticagrelor, a directacting, potent, fast-acting P2Y12 inhibitor, were assessed for the prevention of major vascular events in patients with acute ischemic stroke or transient ischemic attack (TIA). Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin. Because of differences in patient demographics and stroke disease pattern in Asia, outcomes of ticagrelor versus aspirin were assessed among Asian patients in a prespecified exploratory analysis. Methods-Baseline demographics, treatment effects, and safety of ticagrelor and aspirin were assessed among Asian patients. Differences in outcomes between groups were assessed using Cox proportional hazard model. Results-A total of 3858 (29.2%) SOCRATES participants were recruited in Asia. Among the Asian patients, the primary end point event occurred in 186 (9.6%) of the 1933 patients treated with ticagrelor, versus 224 (11.6%) of the 1925 patients treated with aspirin (hazard ratio, 0.81; 95% confidence interval, 0.67-0.99). The exploratory P value for treatment-byregion interaction was 0.27. The primary end point event rate in the Asian subgroup was numerically higher than that in the non-Asian group (10.6% versus 5.7%; nominal P<0.01). Among the Asian patients, the rate of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeding was similar in the ticagrelor group and the aspirin group (0.6% versus 0.8%; hazard ratio, 0.76; 95% confidence interval, 0.36-1.61). Conclusions-The event rates were numerically higher in the Asian patients. Among the Asian patients with acute stroke or transient ischemic attacks, there was a trend toward a lower hazard ratio in reducing risk of the primary end point of stroke, myocardial infarction, or death in the ticagrelor group. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01994720.
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The prevalence of intracranial atherosclerosis was 30% to 50% in Asian patients with ischemic stroke, compared with 8% in white patients. 3, 4 This suggests that P2Y12 inhibitors, including ticagrelor, may be more effective in patients in Asian than those in non-Asian regions. Furthermore, Asian patients, with lower body weight, than white patients, are thought to be more susceptible to bleeding, 5 which might be a concern when treating Asian patients with acute stroke with a potent antiplatelet drug like ticagrelor.
Because of differences in patient demographics, epidemiology and disease patterns in Asia, efficacy and safety of ticagrelor versus aspirin were assessed as to whether they were consistent among Asians and non-Asians who participated in the SOCRATES trial. We report the Asian subgroup results of the SOCRATES trial in this article.
Methods
Overview of the SOCRATES Trial
Details on the rationale, design, and results of the SOCRATES trial have been published previously. 1, 2 The SOCRATES trial was a multicenter, randomized, double-blind, double-dummy, parallel-group trial, which was sponsored by AstraZeneca and conducted at 674 sites in 33 countries between January 7, 2014, and October 29, 2015. The objective of the SOCRATES trial was to compare ticagrelor (180 mg QD on day 1 followed by 90 mg BID on day 2-90) with aspirin (300 mg on day 1, followed by 100 mg daily on day 2-90) for the prevention of major vascular events (a composite of stroke, myocardial infarction, or death) over a period of 90 days in patients with acute ischemic stroke or TIA.
Eligible patients were aged ≥40 years, had an acute ischemic stroke with a National Institutes of Health Stroke Scale score of 5 or lower or had high-risk TIA (ABCD2 stroke risk score of ≥4 [scores assessing the risk of stroke on the basis of age, blood pressure, clinical features, duration of TIA, and presence or absence of diabetes mellitus] or symptomatic intracranial or extracranial arterial stenosis), and could undergo randomization within 24 hours after symptom onset. Details of inclusion and exclusion criteria were provided in the study protocol. 1 The trial was approved by the ethics committee at each study site. Written informed consent was obtained before data collection.
Analysis of the Asian Cohort
An exploratory analysis of data from patients from 206 sites in 8 geographic areas in Asia (China mainland, Hong Kong, Taiwan, Japan, South Korea, Philippines, Thailand, and Vietnam) who participated in the SOCRATES trial was performed. These 8 areas were considered to be the most representative of the Asian region as a whole. Patients enrolled in the SOCRATES trial in the Asian region were also randomized to the 2 treatment groups as the SOCRATES trial used central randomization through an interactive voice/web response system with center as a stratification factor for the randomization process.
Outcome
The primary efficacy outcome was the time from randomization to the first occurrence of any event from the composite of stroke (ischemic or hemorrhagic), myocardial infarction, or death. The secondary efficacy outcome was the time to ischemic stroke. The safety outcomes included time to first major bleeding event, assessed with the use of the PLATO bleeding definition 6 ; time to discontinuation of study treatment as a result of any bleeding event; incidence of intracranial hemorrhage; incidence of fatal bleeding; and incidence of serious and selected nonserious adverse events. The definitions of stroke, myocardial infarction, death, and bleeding were consistent with previously reported major outcomes of the SOCRATES trial.
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Statistical Analysis
This Asian subgroup was prespecified. This analysis was entirely exploratory and hypothesis generating because the overall trial did not meet its primary hypothesis. All analyses were performed with SAS software version 9.4 (SAS Institute Inc, Cary, NC).
Baseline characteristics were compared for patients in the Asian region and those outside the Asian region in the SOCRATES trial. Categorical variables were presented as percentages and continuous variables as median with interquartile range or mean with SD according to the normality of their distribution. χ 2 test and t test were performed for comparison of categorical variables and continuous variables, respectively.
All efficacy analyses were performed in the intention-to-treat population and included all patients who were randomized. All patients who had received at least 1 dose of study treatment were included in the safety analysis set. Safety events occurring within 7 days after intake of the last dose of study treatment were included in the safety outcomes. Event rates were estimated by Kaplan-Meier method. Cox proportional hazards regression models were used with treatment assignment (ticagrelor versus aspirin), region (in Asia versus outside Asia), and interaction of treatment assignment by region as covariates to test for interaction between the differential effects of ticagrelor on all outcomes among Asian patients and non-Asian patients.
Differences between study groups in all end points within the Asian population were assessed using Cox proportional hazards regression model. Hazard ratios with 95% CIs are reported. were randomized from the Asian region in the SOCRATES trial. This accounts for 29.2% of the 13 199 patients in the SOCRATES trial. Among the 3858 patients randomized in the Asian region, the average age was 64.4 years (SD 11.4), and 1395 (36.2%) were women. Compared with participants outside Asia, the Asian patients in the SOCRATES trial were younger, were less likely to be women, had lower body mass index, had fewer vascular risk factors (history of hypertension, dyslipidemia, TIA, myocardial infarction, coronary artery disease, and congestive heart failure), and had a lower proportion taking aspirin, antihypertensive, glucose-lowering agents, and statins before randomization. In the Asian patients, the qualifying event was less often TIA and more often stroke, but with a slightly lower severity (Table I in the online-only Data Supplement). Among the 3858 Asian patients, 1933 patients were assigned to the ticagrelor treatment group and 1925 to the aspirin treatment group. The baseline characteristics of the 2 groups were well balanced (Table II in 
Results
Patient Recruitment and Baseline Characteristics
Efficacy Outcomes
In the Asian subgroup, the observed primary end point event rates in patients treated with ticagrelor (186 [9.6%] of the 1933 patients) was numerically lower than those in the patients treated with aspirin (224 [11.6%] Table 1 ). There was a strong trend toward reduction of the primary end point event and ischemic stroke in the ticagrelor treatment group compared with the aspirin group. The efficacy of ticagrelor for other secondary outcomes is shown in Table 1 .
No significant interaction between treatment assignment and region for primary efficacy outcome was identified (P for interaction=0.27; Table 1 ). The efficacy of ticagrelor versus aspirin for primary efficacy outcome was therefore consistent among participant in Asia and outside Asia. However, the primary end point event rate in the Asian subgroup was numerically higher than that in the non-Asian group (10.6% versus 5.7%; adjusted HR, 1.98; 95% CI, 1.71-2.30; nominal P<0.01; Table 2 ). Results were similar for the outcome of ischemic stroke.
Safety Outcomes
In the Asian subgroup, a primary safety end point event (PLATO-defined major bleeding) occurred in 12 (0.6%) patients in the ticagrelor group and 16 (0.8%) patients in the aspirin group (HR, 0.76; 95% CI, 0.36-1.61; P=0.47; Table 1 ). The safety of ticagrelor versus aspirin was consistent among patients in Asia and outside Asia (P for interaction=0.76; Table 1 ). Results were similar for major or minor bleeding event. However, the major or minor bleeding event rate in the Asian subgroup was numerically higher than that in the non-Asian group (2.1% versus 1.2%; adjusted HR, 1.86; 95% CI, 1.33-2.59; nominal P<0.01; Table 2 ).
As for the net clinical outcome, defined as a composite of stroke, myocardial infarction, death, or life-threatening †Disabling stroke is defined as a new stroke where the patient had a subsequent modified Rankin Scale score of 2 to 6 (indicating death or any degree of disability). ‡The safety end points involved bleeding according to the PLATO definition. Fatal/life-threatening bleed includes bleeding events that meet any of the following criteria: fatal bleeding; intracranial bleeding; intrapericardial bleeding with cardiac tamponade; hypovolemic shock or severe hypotension because of bleeding and requiring pressors/inotropes or surgery; decline in hemoglobin of ≥5 g/dL (or, when hemoglobin is not available, a fall in hematocrit of ≥15%); transfusion of ≥4 units (whole blood or packed red blood cells) for bleeding. Other major bleed includes bleeding events that meet any of the following criteria: significantly disabling (eg, intraocular with permanent vision loss); clinically overt or apparent bleeding associated with a decrease in hemoglobin of 3-5 g/dL (or, when hemoglobin is not available, a fall in hematocrit of 9 to <15%); transfusion of 2-3 U (whole blood or packed red blood cells) for bleeding.
bleeding, the observed event rate in the ticagrelor group was numerically lower than that in the aspirin group (9.9% versus 11.9%; nominal P=0.04; Table 1 ).
Serious adverse events and adverse events leading to discontinuation of study drug by system organ class in each treatment group in Asian patients are listed in Tables III and IV in the online-only Data Supplement.
Discussion
In this prespecified, exploratory regional analysis of the SOCRATES trial, we assessed the efficacy and safety of ticagrelor versus aspirin among Asian patients with acute ischemic stroke or TIA and compared results with those outside Asia. Although the event rates were numerically higher in the Asian patients, the relative efficacy and safety of ticagrelor among the Asian patients were consistent with those in the non-Asian patients. Among the Asian patients, there was a trend toward a lower HR in reducing risk of stroke, myocardial infarction, or death in the ticagrelor group.
The rates of primary end point events and ischemic stroke were ≈2-fold higher in the Asian patients than in the nonAsians. This was verified by the relatively higher 1-year stroke risk after minor stroke or TIA in the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events) 7 performed in China (10.6% in the clopidogrel-aspirin group and 14.0% in the aspirin group) than that in the recently published results from the TIAregistry. org project (5.1%). 8 A similar finding was also observed in the Asian subgroup analysis of the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), in which rates of stroke were also ≈ 2-fold higher in Asian patients than in non-Asian patients. 9 The high event risk in the Asian population could potentially be explained by the difference in disease patterns and stroke care in Asia. First, the proportion of patients aged <65 years was higher in Asian patients and the event rate difference between Asian and non-Asian was highest in this age group. Second, the qualifying event was less often TIA and more often stroke in the Asian patients in this trial. This may be . ‡Disabling stroke is defined as a new stroke where the patient had a subsequent modified Rankin Scale score of 2 to 6 (indicating death or any degree of disability). §The safety end points involved bleeding according to the PLATO definition. Fatal/life-threatening bleed includes bleeding events that meet any of the following criteria: fatal bleeding; intracranial bleeding; intrapericardial bleeding with cardiac tamponade; hypovolemic shock or severe hypotension because of bleeding and requiring pressors/inotropes or surgery; decline in hemoglobin of ≥5 g/dL (or, when hemoglobin is not available, a fall in hematocrit of ≥15%); transfusion of ≥4 units (whole blood or packed red blood cells) for bleeding. Other major bleed includes bleeding events that meet any of the following criteria: significantly disabling (eg, intraocular with permanent vision loss); clinically overt or apparent bleeding associated with a decrease in hemoglobin of 3-5 g/dL (or, when hemoglobin is not available, a fall in hematocrit of 9 to <15%); transfusion of 2-3 U (whole blood or packed red blood cells) for bleeding. The number of patients included in the analysis of safety outcomes was 3828 in the Asian group and 9302 in the non-Asian group.
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because of poor hospitalization rate of the TIA in Asian countries. 10 Finally, although Asian patients had fewer vascular risk factors, secondary stroke prevention strategies (eg, oral anticoagulation in the event of atrial fibrillation, statins, and antihypertensive drugs) were relatively worse and had a delayed implementation in Asian countries. 8, [11] [12] [13] Although no significant treatment-by-region interaction was identified, there was a trend toward a lower HR in reducing risk of primary end points in the ticagrelor group among the Asian patients. The potential relative favorer efficacy of ticagrelor in the Asians compared with the non-Asians may also be attributed to the relative higher prevalence of intracranial atherosclerosis and poorer baseline stroke care in Asian countries.
A numerically higher major or minor bleeding event rate was identified in the Asian group although the major bleeding event was similar between patients in the Asian and non-Asian regions. Increased risk of bleeding in Asian patients was also found in other previous studies. 14, 15 One potential explanation for the increased bleeding risk was the lower body weight in Asian patients compared with white patients. 5 It is verified in this study that the Asian patients had a lower body mass index than the non-Asian patients. Furthermore, the qualifying event was less often TIA and more often stroke in the Asian group in this study. Minor ischemic stroke was found to be more susceptible to bleeding than TIA in the CHANCE trial. 16 Increased bleeding risk should still be a concern when prescribing potent antiplatelet drugs in Asian patients.
This study has several limitations. The overall trial failed to meet its primary hypothesis, and the presented results are exploratory and hypothesis generating; therefore, all the P values are nominal. Furthermore, the number of Asians (3,858) is relatively small when compared with that of non-Asians (9341). Therefore, caution is warranted when explaining the results of subgroup analysis of this trial.
Conclusions
The present exploratory study showed that the efficacy and safety of ticagrelor versus aspirin in Asian patients with acute stroke or TIAs were consistent with those in non-Asians. The event rates were numerically higher in the Asian patients, and there was a trend toward a lower HR in reducing risk of the composite of stroke, myocardial infarction, or death in the ticagrelor group among the Asian patients.
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